Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
97 participants
INTERVENTIONAL
2001-11-30
2005-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Does soy protein alone affect bone metabolism?
2. Do isoflavones, given with soy protein, affect bone metabolism?
3. What dose of isoflavones affects bone in older women?
We hypothesize that soy protein will have a beneficial effect on bone in older women compared to control protein. Further, we hypothesize that there will be an additional benefit to bone in women who receive soy protein plus isoflavones (at both doses) compared to soy protein alone.
Both control and soy proteins used in the study were isolates, meaning they were the highest concentration of protein (85-90% by weight) in order to minimize the volume of protein supplement that each woman was asked to ingest on a daily basis. The soy protein was an alcohol-washed, soy protein isolate containing 90% protein and negligible isoflavone (0.2 mg/g product). The control protein was a mix consisting of 50% protein from sodium caseinate, 25% protein from whey protein and 25% from egg white protein. The use of a mix of proteins as a control provides a more balanced level of amino acids, mimics the real life mix of proteins that humans typically consume, and avoids the unique characteristics of one source of protein. In order to maintain the dietary protein intake constant, the participant was counseled to decrease her intake of other sources of protein from primarily animal sources by approximately 3 ounces per day (the approximate equivalent of the protein powders). The isoflavones tablets each contained 57 mg of total isoflavone from primarily genistein, glycitein, and daidzein and their beta-glycosides.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Soy protein and isoflavone tablets
Soy Isolate
20 grams of powder mixed in beverages or food daily for one year
Novasoy isoflavones
3 tablets daily for one year
2
Soy protein and placebo tablets
Soy Isolate
20 grams of powder mixed in beverages or food daily for one year
Placebo tablets
3 tablets daily for one year
3
control protein and Isoflavone tablets
Control protein
20 grams of powder mixed in beverages or food daily for one year
Novasoy isoflavones
3 tablets daily for one year
4
control protein and placebo tablets
Control protein
20 grams of powder mixed in beverages or food daily for one year
Placebo tablets
3 tablets daily for one year
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Soy Isolate
20 grams of powder mixed in beverages or food daily for one year
Control protein
20 grams of powder mixed in beverages or food daily for one year
Novasoy isoflavones
3 tablets daily for one year
Placebo tablets
3 tablets daily for one year
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to travel to the clinical sites for follow-up visits
Exclusion Criteria
* Cancer of any kind (except basal or squamous cell of skin) in past 5 years
* Use of any of the following medications within the past 2 years: calcitonin, calcitriol, heparin, phenytoin, phenobarbital
* Use at any time of bisphosphonates, long-term corticosteroids (over 6 months), methotrexate, or fluoride
* Estimated creatinine clearance less than 50 ml/min
* History of chronic liver disease or evidence of liver disease on screening
* History of hip fracture
* Known vertebral fracture within the past year
* Vegans
65 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Connecticut
OTHER
United States Department of Agriculture (USDA)
FED
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Connecticut Center on Aging
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jane Kerstetter, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Allied Health Sciences, University of Connecticut
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Connecticut Health Center
Farmington, Connecticut, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Evans EM, Racette SB, Van Pelt RE, Peterson LR, Villareal DT. Effects of soy protein isolate and moderate exercise on bone turnover and bone mineral density in postmenopausal women. Menopause. 2007 May-Jun;14(3 Pt 1):481-8. doi: 10.1097/01.gme.0000243570.78570.f7.
Alekel DL, Germain AS, Peterson CT, Hanson KB, Stewart JW, Toda T. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr. 2000 Sep;72(3):844-52. doi: 10.1093/ajcn/72.3.844.
Arjmandi BH, Lucas EA, Khalil DA, Devareddy L, Smith BJ, McDonald J, Arquitt AB, Payton ME, Mason C. One year soy protein supplementation has positive effects on bone formation markers but not bone density in postmenopausal women. Nutr J. 2005 Feb 23;4:8. doi: 10.1186/1475-2891-4-8.
Kenny AM, Mangano KM, Abourizk RH, Bruno RS, Anamani DE, Kleppinger A, Walsh SJ, Prestwood KM, Kerstetter JE. Soy proteins and isoflavones affect bone mineral density in older women: a randomized controlled trial. Am J Clin Nutr. 2009 Jul;90(1):234-42. doi: 10.3945/ajcn.2009.27600. Epub 2009 May 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
USDA CONR-2001-00630
Identifier Type: -
Identifier Source: secondary_id
AG0102
Identifier Type: -
Identifier Source: org_study_id